

From diagnosis to remission in PsA: prioritising what patients value most

# **From diagnosis to remission in PsA: prioritising what patients value most**

## **Test Lunch and Learn Agenda**

- Agenda
- 12:30 12:35 PM

---

Welcome & Introduction

Mark Taylor

12:35 01:15 PM

---

From diagnosis to remission in PsA: prioritising what patients

Prof. Philip Conaghan

01:15 01:30 PM

---

Q & A

Speakers



prof

Philip

Conaghan

**Learn at Lunch is a CPD accredited webinar series designed for healthcare professionals to learn and discuss the latest advancements in dermatology and rheumatology while exploring the role of Cosentyx® (secukinumab) across its indications, during lunch time.**

### **Speaker Bio**

Professor Philip Conaghan is the director of the NIHR Leeds Biomedical Research Centre; Prof. of Musculoskeletal Medicine for UoL, Honorary Consultant Rheumatologist for LTHT; NIHR Senior Investigator Emeritus. My current national roles include; Chair of several Trial Steering Committees and Data Monitoring Committees, member of NICE Expert Advisor Panel and Trustee of Primary Care Rheumatology Society.

His prior national roles included; Chair of NICE OA Clinical Guidance, 2008 and 2014, Chair of the Arthritis Research UK Osteoarthritis and Crystal Disorders Clinical Studies Group, 2007 – 2017, responsible for national research priority setting.

His current international roles include; Deputy Chair of the international outcomes group OMERACT, qualified EULAR Methodologist, member of scientific committee and EULAR Imaging Course. His prior international roles included; Inaugural Chair of the EULAR Standing Committee on Musculoskeletal Imaging, Treasurer for the European Foundation for Research In Rheumatology (FOREUM) and President of the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR).

He has authored over 650 Pubmed listed publications, cited over 40,000 times, served on a number of editorial boards for leading rheumatology journals, and been co-editor of the current Oxford Textbook of Rheumatology.

## **Register now**

Salutation

- Select - ▼

First name

Last name

e-mail

Required field

Adverse events should be reported. Reporting forms and information can be found at

[www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:**

*<https://www.pro.novartis.com/uk-en/diagnosis-remission-psa-prioritising-what-patients-value-most>*